Table 1.
Demographics of patients who developed submacular hemorrhage and/or retinal vein occlusion after COVID-19 vaccination.
| Category | Value |
|---|---|
| Sex | |
| Male | 11 (52%) |
| Female | 10 (48%) |
| Age (Median) | 77 (range: 51–85 years) |
| Laterality | |
| Unilateral | 19 (90%) |
| Bilateral | 2 (10%) |
|
Diagnosis (Eyes) AMD |
12 (52%) |
| RVO | 11 (48%) |
| Medical History | |
| DM | 9 (43%) |
| HTN | 11 (48%) |
| Type of Vaccination | |
| Pfizer (BNT162b2) | 12 (61%) |
| AstraZeneca (ChAdOx1) | 8 (38%) |
| Number of Vaccination | |
| 1st | 17 (81%) |
| 2nd | 4 (19%) |
| Visual Acuity before Symptom Development (logMAR) | 0.76 (interquartile range: 0.27–1.23) |
| Visual Acuity at Symptom Presentation (logmar) | 1.40 (interquartile range 0.52–1.70) |
| Time between Vaccination and Symptom Aggravation | 2.0 days (interquartile range: 1.0–3.0 days). |
AMD = age-related macular degeneration; DM = diabetes mellitus; HTN = hypertension; LogMAR = logarithm of the minimal angle of resolution.